References - Neonatal Intensive Care Drug Manual

|
Neonatal Intensive Care Drug Manual
|
bet | 434/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
References
NICE Guideline 2015. Gastro-oesophageal reflux disease in children and young people: diagnosis and management. Published: 14 January 2015. nice.org.uk/guidance/ng1.
Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E,Liptak G, Mazur L, Sondheimer J, Staiano,A, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
Shawyer AC, D'Souza J, Pemberton J, Flageole H. The management of postoperative reflux in congenital esophageal atresia-tracheoesophageal fistula: a systematic review. Pediatr Surg Int [Internet]. 2014 [cited 2014 Oct];30(10):987-96. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25011995.
TigheM, AfzalNA, BevanA,HayenA,MunroA, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD008550. DOI: 10.1002/14651858.CD008550.pub2.
Freedberg DE, Lamouse-Smith ES, Lightdale JR, Jin Z, Yang YX, Abrams JA. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis [Internet]. 2015 [cited 2015 Sep 15];61(6):912-7. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=26060292
Jimenez J, Drees M, Loveridge-Lenza B, Eppes S, delRosario F. Exposure to Gastric Acid-Suppression Therapy Is Associated With Health Care- and Community-Associated Clostridium difficile Infection in Children. J Pediatr Gastroenterol Nutr [Internet]. 2015 [cited 2015 Aug];61(2):208-11. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25806678
Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol [Internet]. 2015 [cited 2015 Aug];80(2):200-8. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25752807
Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr [Internet]. 2009 [cited 2009 Oct];155(4):516-21. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=19540518.
Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A, Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics [Internet]. 2006 [cited 2006 May];117(5):e817-20. In: Ovid MEDLINE(R) [Internet]. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=16651285.
Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20:1119–24.
More K, Athalye-Jape G, Rao S, Patole S.Association of inhibitors of gastric acid secretion and higher incidence of necrotizing enterocolitis in preterm very low-birth-weight infants. Am J Perinatol. 2013 Nov;30(10):849-56.
Kierkus J, Furmaga-Jablonska W, Sullivan JE, et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Dig Dis Sci. 2011 Feb;56(2):425-34. doi: 10.1007/s10620-010-1321-3. Epub 2010 Jul 7.
Ward RM, Kearns GL. Proton Pump Inhibitors in Pediatrics. Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics. Pediatr Drugs (2013) 15:119–131. DOI 10.1007/s40272-013-0012-x.
Original version Date: 24/08/2016
Author: NeoMed Consensus Group
Current Version number: 2
Current Version Date: 2/3/2021
Risk Rating: Medium
Due for Review: 2/3/2024
Approved by: DTC
Approval Date: TBA
|
| |